Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A study to collect blood samples and tissue samples to look at the genes of early lung cancer detected through screening (ASCENT)
Cancer type:
Lung cancer
Non small cell lung cancer
Status:
Open
Phase:
Other
This study is collecting blood and tissue samples from people diagnosed with lung cancer. It is also for people suspected of having lung cancer. It is open to people who took part in the:
More about this trial
The SUMMIT study and the NHS Targeted Lung Heath Check (NTLHC) programme are looking at using low dose 
to diagnose lung cancer. As part of the SUMMIT study if your CT scan shows you have lung cancer or might have lung cancer you have surgery to remove it.
In the ACCENT study the team take blood samples. They also take a piece of the lung tissue that the surgeon removes during surgery. They use these samples to look at the of the cancer cells and .
They also look at the results of any scans or tests you have from the time of screening to surgery. The team want to see if they can identify patterns that might suggest lung cancer. Their hope is that by doing this in the future doctors might be able to better understand and diagnose lung cancer.
Please note you won’t get any direct benefit from taking part. The researchers hope that what they learn from this study might help doctors improve the diagnosis of lung cancer.
Who can enter
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this study if you are taking part in the SUMMIT study or the NTLHC programme and all of the following apply. You:
- have lung cancer or might have lung cancer
- are to have or have had surgery to remove the cancer
Who can’t take part
You cannot join this study if any of these apply. You:
- are to have chemotherapy or radiotherapy to shrink the cancer before surgery (neo adjuvant treatment)
- have an active infection of HIV, hepatitis B, hepatitis C or syphilis
Trial design
The study team need about 336 people who took part in the SUMMIT study or the NTLHC programme to join.
The team want people who are to have surgery or have already had surgery to join.
People who are to have surgery
You give 4 samples of blood. You give these on the day you have surgery.
The team take a small sample of the tissue () removed during surgery.
People who have already had surgery
The team ask for a small sample of the tissue removed from when you had surgery.
They use these samples to look at the and for . They will also look at the results of any scans you have and compare them. This is to see if they can find any patterns that might suggest better ways to diagnose lung cancer in the future.
Hospital visits
There are no extra hospital visits in this study.
Side effects
There are no side effects apart from some possible slight bleeding or bruising from the blood samples.
Location
London
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Professor Sam Janes
Supported by
Cancer Research UK
University College London (UCL)
National Institute for Health Research (NIHR)
Freephone 0808 800 4040
Last review date
CRUK internal database number:
17224
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Around 1 in 5 people take part in clinical trials
